1. Rivas P, Morello J, Garrido C, Rodriguez-Novoa S, Soriano V . Role of atazanavir in the treatment of HIV infection. Ther Clin Risk Manag 2009; 5: 99–116.
2. Reyataz product information [homepage on the Internet]. Bristol-Myers Squibb Company; Princeton, NJ 08543, USA: [cited 8 March 2014]. Available from:
http://packageinserts.bms.com/pi/pi_reyataz.pdf
.
3. Bristol-Myers Squibb Company. BMS-232632, atazanavir briefing document, May 2003. [homepage on the Internet]. [cited 8 March 2014]. Available from:
http://www.fda.gov/ohrms/dockets/ac/03/briefing/3950B1_01_BristolMyersSquibb-Atazanavir.pdf
4. Girgis I, Gualberti J, Langan L, Malek S, Mustaciuolo V, Costantino T, et al. A prospective study of the effect of IV pentamidine therapy on ventricular arrhythmias and QTc prolongation in HIV-infected patients. Chest 1997; 112: 646–53.
5. Castillo R, Pedalino RP, El-Sherif N, Turitto G . Efavirenz-associated QT prolongation and Torsade de Pointes arrhythmia. Ann Pharmacother 2002; 36: 1006–8.